Recent Pfizer Press Releases
NEW YORK, N.Y., June 19 – Pfizer Inc. (NYSE: PFE) today announced the final exchange ratio in connection with its previously announced offer to its shareholders to exchange some or all of their shares of Pfizer common stock for shares of Zoetis Inc. (NYSE: ZTS) common stock held by Pfizer.
NEW YORK, N.Y., June 12 – Pfizer Inc. announced today a $2.15 billion settlement reached with Teva Pharmaceuticals Industries, Limited and Sun Pharmaceutical Industries, Limited for patent-infringement damages resulting from their "at-risk” launches of generic Protonix® in the United States. The settlement comes after a nearly 10-year legal battle in which Pfizer and Nycomed (now part of Takeda) sought to enforce the patent for its blockbuster acid reflux medicine. Pfizer and Takeda will divide the proceeds of the settlement with Pfizer receiving 64 percent.
(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Geno Germano, President and General Manager, Specialty Care and Oncology, at the Goldman Sachs 34th Annual Global Healthcare Conference on Thursday, June 13, 2013 at 8:40 a.m. Pacific Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Goldman Sachs 34th Annual Global Healthcare Conference”
more...
Pfizer and Generations United Challenge People and Communities to Define How They Want to Get Old
(BUSINESS WIRE)--Nearly nine out of ten people who live in the U.S. believe they will live a long life, yet 40 percent believe being old is something to fear due to potential health and financial concerns, according to the second annual Get Old survey. Despite rising rates of chronic disease estimated to affect nearly half (49%) the U.S. population by 2025, survey respondents expressed a surprising degree of comfort with the current state of theirmore...
more...
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering
consisting of five tranches of notes:
$750,000,000 aggregate principal amount of 0.900% notes due 2017
$1,000,000,000 aggregate principal amount of 1.500% notes due 2018
$500,000,000 aggregate principal amount of floating rate notes due 2018
$1,000,000,000 aggregate principal amount of 3.000% notes due 2023more...
more...
Provides Pfizer shareholders an option for a tax-free exchange
Better positions Pfizer to focus on its core business as an innovative biopharmaceutical company
The completion of the full separation of Zoetis expected to be accretive to Pfizer’s EPS beginning in 2014
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced its intention to split off its
remaining interest in Zoetis Inc. (NYSE: ZTS), through an exchange
offer. Zoetis, formerly Pfizer’s animal health business, completed its
initial public offering (IPO) in February 2013. In the exchange offer,
Pfizer shareholders can exchange all, some or none of their shares of
Pfizer common stock for shares of Zoetis common stock owned by Pfizer.
The exchange offer ismore...
Pfizer to Continue Evaluation of Inotuzumab Ozogamicin in Other Hematologic Malignancies
(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of a Phase 3 randomized,
open-label, two-arm study (B1931008) evaluating the safety and efficacy
of the investigational compound inotuzumab ozogamicin in patients with
relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who
are not candidates for intensive high-dose chemotherapy. In this study,
inotuzumab ozogamicin was administered on a once-a-month schedule in
combination withmore...
NEW YORK and CARMIEL, Israel--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX, TASE: PLX) today announced the submission of a Marketing Authorization Application to the European Medicines Agency for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD)for the treatment of Gaucher disease. Taliglucerase alfa was granted Orphan Designation by the European Commission for the treatment of
more...
(BUSINESS WIRE) Pfizer Inc announced today that the Court of Appeals for the Federal Circuit has upheld the two main U.S. patents covering Celebrex, the company’s selective non-steroidal anti-inflammatory (NSAID) medicine used to treat pain and inflammation. The patents had been challenged by generic manufacturer Teva Pharmaceuticals USA. The panel ruled that the patents (Nos. 5,466,823 and 5,563,165) covering the
more...
Additional Analyses Further Evaluate Safety and Efficacy of Tofacitinib in Rheumatoid Arthritis
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that 11 abstracts for
tofacitinib will be presented at the European League Against Rheumatism
(EULAR) 2013 Annual Meeting being held June 12-15 in Madrid, Spain. The
brand name for tofacitinib is XELJANZ® (ZEL’ JANS’).
Highlights include:
Comparison of monotherapy vs. combination therapy with tofacitinib
A meta-analysis of four Phase 3 trials (ORAL Sync, Standard, Scanmore...
more...
(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen
to a webcast of a presentation by Mikael Dolsten, President, Worldwide
Research and Development, at the Morgan Stanley 2013 R&D Seminar:
Reigniting Pharma on Friday, May 10, 2013 at 11:00 a.m. Eastern Daylight
Time.
To view and listen to the webcast, visit our web site at www.pfizer.com
and click on the “Morgan Stanley 2013 R&D Seminar: Reigniting Pharmamore...
Subgroup analysis demonstrates that the treatment effects of Eliquis® (apixaban) vs. warfarin, across a broad range of warfarin control, are consistent with primary results of ARISTOTLE
ARISTOTLE studied Eliquis vs. warfarin for the reduction of the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from this subanalysis showed that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis® (apixaban) compared to warfarin in the ARISTOTLE trial were consistent acrossmore...
more...
(BUSINESS WIRE)--To meet the needs of consumers who are increasingly going online to purchase prescription medications, Pfizer today launched Viagra® home delivery, a new prescription-fulfillment website for Viagra® (sildenafil citrate) tablets, Pfizer’s most counterfeited medicine. The site, which is powered by CVS/pharmacy and accessible through Viagra.com, offers men with erectile dysfunction (ED) an opportunity to purchase Viagra online (with a validmore...
more...
First-Quarter 2013 Revenues of $13.5 Billion, including All Zoetis(1) Revenues
First-Quarter 2013 Adjusted Diluted EPS(2) of $0.54, Reported Diluted EPS(3) of $0.38
Repurchased $6.3 Billion of Common Stock to Date in 2013
Updates 2013 Adjusted Diluted EPS(2) Guidance to Reflect the Impact of Recent Changes in Foreign Exchange Rates and the Zoetis(1) Initial Public Offering
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter
2013 and updated certain components of its 2013 financial guidance to
reflect the impact of recent changes in foreign exchange rates and the
initial public offering (IPO) of a 19.8% ownership interest in Zoetis(1)
completed on February 6, 2013, among other factors. Pfizer continues to
consolidate Zoetis(1), as Pfizer retains an 80.2% ownership
interest. The earningsmore...
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada (“Merck”), and Pfizer Inc. (NYSE:PFE) today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer’s ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes. Ertugliflozin is Phase III ready, with trials expected to begin later inmore...
more...
(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49 years of age. The study met all primary and secondary objectives and provides the clinical foundation for the Company’s regulatory submission in the European Union (EU) and planned regulatory submissions in the Unitedmore...
more...
Pfizer Intends to Appeal and Seek Re-Examination
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for XELJANZ® (tofacitinib citrate) for the treatment of adult patients with moderate-to-severe active rheumatoid arthritis (RA). The CHMP is of the opinion that XELJANZ does not demonstrate a favorable risk:benefit profile at this time and recommended against marketingmore...
more...
Declares 24-Cent Second-Quarter 2013 Dividend
(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 24-cent
second-quarter 2013 dividend on the company’s common stock, payable June
4, 2013, to shareholders of record at the close of business on May 10,
2013. The second-quarter 2013 cash dividend will be the 298th
consecutive quarterly dividend paid by Pfizer.
“Through dividends and share repurchases, we returned approximately $15
billion to our shareholders in 2012,” said Ian Readmore...
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced top-line results for a Phase 4
clinical trial in which the primary objective was to measure blood
pressure (hypertension) among pediatric patients with Juvenile
Idiopathic Arthritis (JIA; also known as Juvenile Rheumatoid Arthritis
or JRA) taking celecoxib (Celebrex) capsules or naproxen.
The results demonstrated there was virtually no difference in changes to
systolic blood pressure, the primarymore...
(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a
webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern
Daylight Time) on Thursday, April 25. To access the webcast, visit our
website at www.pfizer.com/annualmeeting
and click on the “Annual Meeting of Shareholders Webcast” link.
Information on accessing and pre-registering for the live audio webcast
will be available at www.pfizer.com
beginningmore...